Systemic 9-valent human papillomavirus vaccine for recalcitrant common cutaneous warts in preparation for renal transplant

Wyant, W. Austin; Burke, George W.; Ioannides, Tim; Nichols, Anna

doi:10.1016/j.jdcr.2022.02.004

Cited by 4 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The systemic routine administration of 2‐valent and 4‐valent HPV vaccines for the treatment of common warts, both in adults and children, has emerged as a promising alternative to traditional modalities 11–17 . Recently, three case reports of systemic routine administration of the 9‐valent HPV vaccine leading to a complete clearance of all existing warts were described 23–25 . In all the three cases, a routine 9‐valent HPV vaccine was given and led to resolution with complete clearance of all the existing warts.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intralesional human papillomavirus vaccine for the treatment of recalcitrant cutaneous warts

Bar‐Ilan,

Bar,

Baniel

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

Human papillomavirus (HPV) is ubiquitously distributed in the population worldwide and its most frequent clinical presentation is cutaneous warts. Despite various treatment options currently available, many patients experience persistent and refractory disease. We sought to evaluate the clinical effectiveness and safety profile of intralesional HPV 9‐valent vaccine for the treatment of recalcitrant warts. A retrospective study was performed for all cases of cutaneous warts treated with intralesional 9‐valent HPV vaccine between January 2017 and March 2021. Epidemiologic, clinical, and treatment data, including safety and effectiveness scores, were reviewed. Our cohort was composed of 20 patients: 13 adults and seven children. Twelve patients (60%) displayed a complete response whereas 8 patients (40%) showed a partial response. Older age was associated with a better response to treatment, while a history of laser therapy was associated with a worse prognosis. Adverse events were local, transient, and negligible. No systemic adverse effects were reported. Intralesional 9‐valent HPV vaccine may be considered for the treatment of recalcitrant cutaneous warts. Controlled studies are required to confirm these results.

show abstract

Section: Discussionmentioning

confidence: 99%

“…[11][12][13][14][15][16][17] Recently, three case reports of systemic routine administration of the 9-valent HPV vaccine leading to a complete clearance of all existing warts were described. [23][24][25] In all the three cases, a routine 9-valent HPV vaccine was given and led to resolution with complete clearance of all the existing warts.…”

Section: Re Sultsmentioning

confidence: 97%

Intralesional human papillomavirus vaccine for the treatment of recalcitrant cutaneous warts

Bar‐Ilan,

Bar,

Baniel

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…There is also recent data demonstrating that in immunosuppressed individuals (HIV-infected, with a SOT history, including KT, or being on medications that suppress the immune system), HPV vaccination was associated with the development of less CIN2 + precancerous lesions ( 9 , 10 ). In addition, there are several case reports describing the resolution of genital and non-genital difficult-to-treat recalcitrant warts after HPV vaccine administration ( 57 , 58 ).…”

Section: Hpv Vaccinationmentioning

confidence: 99%

Human papillomavirus infection-related cancer risk for kidney transplant recipients during adult life can be reduced by vaccination during childhood and adolescence

Nailescu

Shew

2022

Front. Pediatr.

View full text Add to dashboard Cite

Malignancies are found between the first three reasons of mortality in pediatric and adult kidney transplant recipients, who overall have disproportionately higher rates of cancer compared to the general population, including human papillomavirus (HPV)-related genital, anal and oropharynx region cancers. Therefore, preventing HPV in this patient population is extremely important. HPV-vaccine was demonstrated to prevent HPV infection in individuals with intact immune systems. In addition, recent data reported less precancerous HPV lesions and cervical cancers with use of HPV vaccine. Since HPV is a sexually transmitted virus that is typically acquired shortly after the onset of sexual activity, it is best to administer the HPV vaccine immunization prior to the onset of sexual activity. This article reviews the epidemiology and pathophysiology of the HPV infection, as well as its role in the development of HPV-related pre-cancerous lesions and cancers in both general population and kidney transplant recipients. The focus is on the most effective primary prophylactic strategy, which is the HPV vaccination. The particularities of HPV vaccination strategies in kidney transplant recipients are compared to the general population. In addition, the article analyzes the various causes of suboptimal HPV immunization rates in kidney transplant candidates and recipients and discusses vaccination optimization strategies that can be applied during childhood and adolescence to reduce the burden of HPV-related disease states and cancer among adult kidney transplant recipients.

show abstract

The mycobiome affects viral susceptibility of skin epithelium

Peterson,

Beck,

Brewer

2024

Journal of Medical Mycology

View full text Add to dashboard Cite

Systemic 9-valent human papillomavirus vaccine for recalcitrant common cutaneous warts in preparation for renal transplant

Cited by 4 publications

References 10 publications

Intralesional human papillomavirus vaccine for the treatment of recalcitrant cutaneous warts

Intralesional human papillomavirus vaccine for the treatment of recalcitrant cutaneous warts

Human papillomavirus infection-related cancer risk for kidney transplant recipients during adult life can be reduced by vaccination during childhood and adolescence

The mycobiome affects viral susceptibility of skin epithelium

Contact Info

Product

Resources

About